US FDA Recalibrates Office Of Generic Drugs
As Part Of Wider Structural Changes To CDER
As part of a wider overhaul of the FDA’s Center for Drug Evaluation and Research, the agency is reorganizing its Office of Generic Drugs, including adding a new Office of Safety and Clinical Evaluation within the OGD.
